Links to Studies

Status Official Title Lead Investigator Last Updated
Finalised Strengthening Use of Real-World Data in Medicines Development: Metadata for Data Discoverability and Study Replicability Dr Susana Perez-Gutthann 21/01/2022
Finalised Cohort Study of the Incidence of Major Cardiovascular Events in New Adult Users of Lisdexamfetamine and Remote Adult Users of Other ADHD Treatments Dr Cristina Rebordosa 23/09/2021
Finalised Intravenous Iron Postauthorisation Safety Study (PASS): Evaluation of the Risk of Severe Hypersensitivity Reactions Mrs Lia Gutierrez 08/09/2021
Finalised Cohort Study of the Relative Incidence of Major Cardiovascular Events Among Patients Initiating Prucalopride Versus a Matched Comparator Cohort Dr Alicia Gilsenan 06/09/2021
Finalised EPID Multiple Sclerosis Pregnancy study - Pregnancy outcomes in Multiple Sclerosis populations exposed and unexposed to interferon beta - a register-based study in the Nordic countries Dr Pasi Korhonen 16/03/2021
Finalised Post-Authorisation Safety Study of Agomelatine and the Risk of Hospitalisation for Acute Liver Injury Dr Manel Pladevall 28/01/2021
Finalised A Population-based Cohort Study of Pregabalin to Characterize Pregnancy Outcomes Professor Vera Ehrenstein 25/08/2020
Finalised Post-authorization Safety Study Evaluation of Cardiovascular Events in Users of Mirabegron and Other Treatments for Overactive Bladder Dr John Seeger 28/04/2020
Finalised Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus, Pimecrolimus, and Corticosteroids Dr Alejandro Arana 22/11/2019
Finalised Post-authorization Safety Study Evaluation of Neoplasm Events in Users of Mirabegron and Other Treatments for Overactive Bladder : Core Common Protocol Dr John Seeger 18/11/2019
Finalised Post-authorization Safety Program Using the Swedish National Registers—A Validation Study of Cardiovascular and Neoplasm Events in Users of Pharmacological Treatments for Overactive Bladder Dr Alejandro Arana 10/04/2019
Finalised An observational cohort study to evaluate the risk of adverse pregnancy outcomes in patients treated with etanercept compared to those not treated with etanercept or other biologics using merged data from Sweden, Denmark and Finland Dr Helle Kieler 19/09/2018
Finalised Cilostazol Drug Utilisation Study Dr Jordi Castellsague 25/07/2018
Finalised A multinational active safety surveillance study of crizotinib in Europe Professor Henrik Toft Sørensen 18/07/2018
Finalised Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus, Pimecrolimus, and Corticosteroids Dr Jordi Castellsague 15/05/2018
Finalised A pharmacoepidemiological study to examine patient characteristics, drug utilizationpattern and crude incidence rates of selected outcomes in new users of ticagrelor,clopidogrel and prasugrel in national Swedish registries. Dr Helle Kieler 24/01/2018
Finalised Pan European Multi-Database Bladder Cancer Risk Characterisation Study Dr Pasi Korhonen 30/05/2017
Finalised A population-based cohort study using an existing database to evaluate the association between latanoprost use and primary malignant ocular melanoma and facial cutaneous melanoma Dr Prethibha George 19/09/2016
Ongoing Pregnancy outcomes in women exposed to oral cladribine: a multi-country cohort database study Dr Alejandro Arana 15/02/2021
Ongoing Pharmacoepidemiological study (Drug Utilization Study) of JAYDESS use in routine clinical practice in Sweden Dr Helle Kieler 14/02/2020
Ongoing A Nationwide Post-Marketing Study on the Safety of Abatacept Treatment in Sweden Using the SRQ Register Ms Alyssa Dominique 31/10/2019
Ongoing An Active Safety Surveillance Program To Monitor Selected Events In Patients With Long-Term Voriconazole Use Professor Helle Kieler 26/02/2018
Ongoing CAncer Risk and INsulin analoGues Dr Marie L De Bruin 11/12/2015
Planned Observational Studies in Cancer Associated Thrombosis for Rivaroxaban in SwEden (OSCAR-SE) Dr Bayer Clinical Trials BAYER AG 14/12/2021
Planned The BRodalumab Assessment of Hazards: A Multinational Safety (BRAHMS) study in electronic healthcare databases Professor Jesper Hallas 05/10/2021
Planned A non-interventional study to examine patient characteristics Ms Novartis Clinical Disclosure Officer 05/05/2021
Planned A post-marketing registry-based prospective cohort study of long-term safety of risankizumab in Denmark and Sweden Professor Helle Kieler 15/04/2021